Vertex Pharmaceuticals Incorporated (VRTX) PEG Ratio: 3.23
Is Vertex Pharmaceuticals Incorporated’s PEG ratio high or low?
Vertex Pharmaceuticals Incorporated's PEG ratio of 3.23 is 120% above its 4-year average of 1.47, near the high end of its 4-year range (0.18–3.48).
24.95% above its 12-month average of 2.58.
VRTX PEG Ratio Chart
VRTX Average PEG Ratio Chart
VRTX Current vs Average PEG Ratio Chart
VRTX PEG Ratio Metrics
PEG RATIO
3.23
PEG RATIO AVG TTM
2.58
PEG RATIO AVG 3Y
1.90
PEG RATIO AVG 5Y
1.47
PEG RATIO AVG 10Y
1.43
PEG RATIO AVG 15Y
1.27
PEG RATIO AVG 20Y
1.15
CURRENT VS TTM AVG
+24.95%
CURRENT VS 3Y AVG
+70.30%
CURRENT VS 5Y AVG
+120.10%
CURRENT VS 10Y AVG
+126.55%
CURRENT VS 15Y AVG
+154.33%
CURRENT VS 20Y AVG
+181.11%
VRTX Competitors' PEG Ratio
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated (VRTX) | $112.92B | 3.23 | 2.58 | 1.90 | 1.47 |
| Bristol-Myers Squibb Company (BMY) | $116.66B | 1.71 | 0.24 | 0.24 | 0.18 |
| Medtronic plc (MDT) | $102.97B | 6.73 | 3.74 | 3.74 | 2.73 |
| Danaher Corporation (DHR) | $127.47B | 87.09 | 1.21 | 1.11 | 1.91 |
| CVS Health Corporation (CVS) | $130.09B | N/A | 0.13 | 1.20 | 1.16 |
| Elevance Health Inc. (ELV) | $87.75B | 2.58 | 6.99 | 4.82 | 3.75 |
| Intuitive Surgical, Inc. (ISRG) | $145.58B | 3.17 | 3.02 | 2.60 | 2.27 |
| Cigna Corporation (CI) | $78.83B | 0.15 | 0.15 | 0.29 | 0.24 |
| Pfizer Inc. (PFE) | $149.38B | N/A | 0.07 | 0.13 | 0.16 |
| Abbott Laboratories (ABT) | $153.59B | 2.99 | 0.11 | 0.36 | 0.87 |
Growth-Adjusted Valuation
PEG Ratio
3.23
P/E Ratio
26.4
Vertex Pharmaceuticals Incorporated PEG Ratio Formula & Definition
PEG Ratio = PE Ratio / Earnings Growth Rate
The PEG ratio adjusts the PE ratio for expected earnings growth. A PEG near 1 is often considered fairly valued relative to growth.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Vertex Pharmaceuticals Incorporated PEG Ratio FAQ
- What is the PEG ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The PEG ratio for VRTX stock is 3.23.
- Is Vertex Pharmaceuticals Incorporated's PEG ratio high or low?
- Vertex Pharmaceuticals Incorporated's PEG ratio of 3.23 is 120% above its 4-year average of 1.47, near the high end of its 4-year range (0.18–3.48).
- What is the TTM average PEG ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The TTM average PEG ratio for VRTX stock is 2.58.
- What is the 3Y average PEG ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 3Y average PEG ratio for VRTX stock is 1.90.
- What is the 5Y average PEG ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 5Y average PEG ratio for VRTX stock is 1.47.
- What is the 10Y average PEG ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 10Y average PEG ratio for VRTX stock is 1.43.
- What is the 15Y average PEG ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 15Y average PEG ratio for VRTX stock is 1.27.
- What is the 20Y average PEG ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 20Y average PEG ratio for VRTX stock is 1.15.
Vertex Pharmaceuticals Incorporated PEG Ratio History
| DATE | PEG RATIO |
|---|---|
| 2024-12-31 | 1.69 |
| 2023-12-31 | 3.48 |
| 2022-12-31 | 0.52 |
| 2020-12-31 | 0.18 |
| 2018-12-31 | 0.03 |
| 2016-12-31 | 2.00 |
| 2015-12-31 | 2.08 |
| 2012-12-31 | 0.18 |
| 2006-12-31 | 1.04 |
| 2004-12-31 | 0.29 |
| 2000-12-31 | 4.65 |
| 1997-12-31 | 0.66 |
Related Metrics
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Reshma Kewalramani